Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Changhoon Yoo

Showing results (241-250 of 251) with videos related to

Pageof 26
Sort By:
Targeted Oncology|February 27, 2026
Prognostic Impact of Metastatic Sites in Patients with Biliary Tract Cancer Treated with Cisplatin, Gemcitabine, and DurvalumabSilvia Camera, Lorenzo Fornaro, Margherita Rimini, et al.
Oncology|October 13, 2024
Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World StudyMara Persano, Andrea Casadei-Gardini, Toshifumi Tada, et al.
Liver Cancer|September 19, 2024
Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter StudyFederico Rossari, Toshifumi Tada, Goki Suda, et al.
International Journal of Cancer|May 19, 2025
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real-world results from a multicenter and multinational studyMargherita Rimini, Lorenzo Fornaro, Federica Lo Prinzi, et al.
Journal of Cancer Research and Clinical Oncology|December 12, 2022
Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world studyMara Persano, Margherita Rimini, Toshifumi Tada, et al.
Journal of the National Cancer Institute|July 3, 2025
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine and durvalumab: a large real-life worldwide populationMargherita Rimini, Lorenzo Fornaro, Federica Lo Prinzi, et al.
International Journal of Cancer|July 11, 2025
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real-life worldwide populationFederica Lo Prinzi, Francesca Salani, Silvia Camera, et al.
Oncology|August 15, 2025
Impact of antibiotic therapy in patients with cholangiocarcinoma treated with chemoimmunotherapyFrancesco Vitiello, Caterina Vivaldi, Mario Domenico Rizzato, et al.
Targeted Oncology|April 30, 2024
Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus BevacizumabMara Persano, Margherita Rimini, Toshifumi Tada, et al.
Targeted Oncology|January 22, 2024
Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular CarcinomaSilvia Camera, Margherita Rimini, Federico Rossari, et al.
Pageof 26

Showing results (241-250 of 251) with videos related to

Sort By:
Pageof 26
Targeted Oncology|February 27, 2026
Prognostic Impact of Metastatic Sites in Patients with Biliary Tract Cancer Treated with Cisplatin, Gemcitabine, and DurvalumabSilvia Camera, Lorenzo Fornaro, Margherita Rimini, et al.
Oncology|October 13, 2024
Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World StudyMara Persano, Andrea Casadei-Gardini, Toshifumi Tada, et al.
Liver Cancer|September 19, 2024
Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter StudyFederico Rossari, Toshifumi Tada, Goki Suda, et al.
International Journal of Cancer|May 19, 2025
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real-world results from a multicenter and multinational studyMargherita Rimini, Lorenzo Fornaro, Federica Lo Prinzi, et al.
Journal of Cancer Research and Clinical Oncology|December 12, 2022
Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world studyMara Persano, Margherita Rimini, Toshifumi Tada, et al.
Journal of the National Cancer Institute|July 3, 2025
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine and durvalumab: a large real-life worldwide populationMargherita Rimini, Lorenzo Fornaro, Federica Lo Prinzi, et al.
International Journal of Cancer|July 11, 2025
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real-life worldwide populationFederica Lo Prinzi, Francesca Salani, Silvia Camera, et al.
Oncology|August 15, 2025
Impact of antibiotic therapy in patients with cholangiocarcinoma treated with chemoimmunotherapyFrancesco Vitiello, Caterina Vivaldi, Mario Domenico Rizzato, et al.
Targeted Oncology|April 30, 2024
Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus BevacizumabMara Persano, Margherita Rimini, Toshifumi Tada, et al.
Targeted Oncology|January 22, 2024
Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular CarcinomaSilvia Camera, Margherita Rimini, Federico Rossari, et al.
Pageof 26